News|Articles|May 27, 2026

Anticipated Data and Practice-Changing Trials: An ASCO 2026 Breast Cancer Preview

Leading experts preview highly anticipated breast cancer data at ASCO 2026, including readouts from the SERENA-6, persevERA, and OPTIMA trials.

The upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is poised to showcase pivotal data that could reframe treatment paradigms across the breast cancer spectrum, from early-stage de-escalation strategies to novel therapeutics for advanced disease. Ahead of the meeting, MinhTri Nguyen, MD, and Nerea Lopetegui, MD, shared their insights with CancerNetwork® on the specific clinical trials, regulatory debates, and emerging modalities generating the most significant professional anticipation.

Related to this article

Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.

November 1st, 2026

Closing the Gaps in Precision Oncology for Breast Cancer

Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.

November 1st, 2026

KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer

Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.

Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.

October 30th, 2026

How Might Duffy-Null Status Shape Breast Cancer Outcomes and Trial Access?

Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.

A Phase 1, Phase 2, and Phase 3 Trial in Gastrointestinal Cancer from ESMO: © PIC4U - stock.adobe.com

October 30th, 2026

Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3

A bispecific in biliary tract cancer, dostarlimab organ preservation in rectal cancer, and KRAS G12D data in pancreatic cancer stood out at ESMO 2026.

October 30th, 2026

Key Multidisciplinary Takeaways for Lung Cancer Care From ESMO 2026

Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.